Veradermics Presents VDPHL01 Data Showing Significant Hair Growth in Two Male Pattern Hair Loss Studies

By Public Technologies
  • Veradermics' VDPHL01 met both co-primary efficacy endpoints with high statistical significance in two registration-directed male pattern hair loss studies.
  • Twice-daily dosing increased six-month target area hair counts by 36.4 in Study 304 versus 6.6 with placebo.
  • Study 302 recorded corresponding increases of 33.0 versus 7.3 with placebo.
  • Patient-reported improvement rates with twice-daily dosing reached 68.7% in Study 304 versus 62.9% in Study 302.
  • The female Phase 2/3 trial is fully enrolled with 556 participants; initial topline data are expected in the first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veradermics Inc. published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.